PMID- 33968678
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210513
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Apr
TI  - UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative 
      review and future perspectives.
PG  - 1908-1917
LID - 10.21037/tau-20-1207 [doi]
AB  - The number of patients with urothelial carcinoma (UC) is high, with a 
      corresponding demand for detecting UC easily and non-invasively. Cystoscopy and 
      urine cytology, with widely known diagnostic accuracies, are the gold standards 
      for identifying UC originating from the bladder. However, cystoscopy or other 
      tests, such as ureteroscopy or retrograde pyelography, are uncomfortable for 
      patients. Tests for urinary biomarkers are expected to satisfy the demand for 
      less invasive tests that will benefit patients with anxiety for invasive tests 
      such as cystoscopy or ureteroscopy. Although several urinary biomarkers have been 
      reported to support the diagnosis or follow-up of UC, their use in the clinic is 
      uncommon. The UroVysion test examines urinary biomarkers using a multitarget, 
      multicolor fluorescence in situ hybridization (FISH) assay. The test uses 
      exfoliated cells found in urine and is a mixture of centromeric fluorescent 
      denatured chromosome enumeration probes for chromosomes 3, 7, and 17 (labelled 
      stratum red, spectrum green and spectrum aqua, respectively), and a 
      locus-specific identifier probe for 9p21 (spectrum gold). It is used for the 
      initial diagnosis of patients with hematuria or the monitoring of patients 
      previously diagnosed with bladder cancer. Almost 20 years have passed since 
      UroVysion was approved by the U.S. Food and Drug Administration, and so this is a 
      well-established test. However, room exists for further research, with numerous 
      reports on this test having been recently published. In order to update our 
      knowledge, we herein present a brief overview of UroVysion and its features that 
      follows the latest findings as they relate to UC.
CI  - 2021 Translational Andrology and Urology. All rights reserved.
FAU - Nagai, Takashi
AU  - Nagai T
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Naiki, Taku
AU  - Naiki T
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Etani, Toshiki
AU  - Etani T
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Iida, Keitaro
AU  - Iida K
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Noda, Yusuke
AU  - Noda Y
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Shimizu, Nobuhiko
AU  - Shimizu N
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Isobe, Teruki
AU  - Isobe T
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Nozaki, Satoshi
AU  - Nozaki S
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Okamura, Takehiko
AU  - Okamura T
AD  - Department of Urology, Anjo Kosei Hospital, Anjo City, Japan.
FAU - Ando, Ryosuke
AU  - Ando R
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Kawai, Noriyasu
AU  - Kawai N
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Yasui, Takahiro
AU  - Yasui T
AD  - Department of Nephro-urology, Nagoya City University, Graduate School of Medical 
      Sciences, Nagoya, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC8100858
OTO - NOTNLM
OT  - UroVysion
OT  - fluorescence in situ hybridization (FISH)
OT  - urothelial cancer
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tau-20-1207). The series "Urinary 
      Biomarkers of Urothelial Malignancies" was commissioned by the editorial office 
      without any funding or sponsorship. The authors have no other conflicts of 
      interest to declare.
EDAT- 2021/05/11 06:00
MHDA- 2021/05/11 06:01
PMCR- 2021/04/01
CRDT- 2021/05/10 06:27
PHST- 2021/05/10 06:27 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/11 06:01 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - tau-10-04-1908 [pii]
AID - 10.21037/tau-20-1207 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2021 Apr;10(4):1908-1917. doi: 10.21037/tau-20-1207.